Concerns rise over breast cancer risk and gender-based efficacy of Ocrevus

[News]

The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS) - a form of MS thought to affect around 15 % of patients.

More... (https://www.news-medical.net/news/20260417/Concerns-rise-over-breast-cancer-risk-and-gender-based-efficacy-of-Ocrevus.aspx)